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ABSTRACT 
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that activates both 
leukocytes and endothelium and facilitates the movement of inflammatory cells from circulation 
to sites of infection or injury. This activation may be beneficial and aid in host defense, or may 
be detrimental and mediate part of the pathophysiology of disease. Several porcine diseases, 
such as salmonellosis and mycoplasmal pneumonia, cause an increase in TNF production, 
which may be either beneficial or harmful to swine health. Two related studies were completed 
to develop assays and reagents to further study the role of TNF in porcine disease. 
In the first smdy, we compared the sensitivity of PK(15) and WEHI 164(13) cells to 
human, murine and porcine TNF-mediated lysis. Our data indicated that the PK(15) cells are 
50 times less sensitive to murine TNF and 15-fold less sensitive to human TNF than are 
WEHI 164(13) cells. The PK(15) ceils are, however, 4 times more sensitive to recombinant 
porcine TNF and 15 times more sensitive to porcine serum containing TNF. Because the 
PK(15)-based bioassay was more sensitive for detecting porcine TNF in serum, this bioassay 
may be particularly useful in the study of infectious disease processes of swine. 
In mice and humans, sepsis and endotoxemia are also accompanied by a rise in 
circulating soluble receptors for TNF. Since there is little known about these receptors during 
porcine sepsis, the objectives of the second study were to clone, express and determine the 
bioactivity of porcine soluble TNF receptor 1 (TNFRl). Using a polymerase chain reaction 
(PCR)-based library enrichment technique, a 927 base pair fragment of porcine TNFRl was 
isolated from a lung cDNA library. The mature extracellular domain consisting of464 amino 
acids of porcine TNFRl was expressed as a FLAG fusion protein in Escherichia coli. An anti-
FLAG affinity column was used to purify the fusion protein. The purified protein at a 
concentration of 5 |ig/ml neutralized 70% of TNF-mediated cytotoxicity in a bioassay. 
Recombinant porcine soluble TNFRl protein and the PK(15) based bioassay may be useful in 
smdying die roles of boda TNF and TNFRl in the pathogenesis of infectious disease of swine. 
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GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation is organized into a literature review, two journal papers, and a general 
conclusion. The literature review focuses on the biology of tumor necrosis factor (TNF), 
specifically the harmful effects of TNF overproduction, the release of soluble TNF receptors, 
the interaction of shed receptor with TNF, and the diagnostic value of measuring soluble TNF 
receptor levels, with an emphasis on the role of TNF in porcine disease. The first paper is a 
smdy comparing two cell lines, PK(15) and WEHI 164(13) for their ability to detect porcine 
TNF in a bioassay. The second paper is a description of the cloning, sequencing and 
expression of porcine soluble TI-^F receptor 1. The first paper has been accepted for 
publication in the American Journal of Veterinary Research (AJVR), and ±e second will be 
submitted for publication to AJVR. 
Literature Review 
Tumor necrosis factor (TNF) is a potent cytokine with a broad spectrum of biological 
activities, ranging from tumor necrosis and immune activation to cachexia. As such, the 
activities of this cytokine have been characterized in humans as well as in several other species. 
Tumor necrosis factor plays a pivotal role in both disease resistance and disease progression in 
many illnesses in a wide variety of species. The amount of information known about TNF is 
too extensive to cover in a single review article. In fact, there have been several reviews 
recently published covering the biology (7,18, 249) and pathophysiology (19,248,263) of 
TNF. The focus of this review will be on the harmful effects of TNF overproduction, 
including the regulation of TNF production, TNF signal transduction, TNF receptor shedding 
and the consequences of soluble TNF receptor interactions with TNF, with an emphasis on the 
role of TNF in porcine disease. 
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Discovery ofTNF 
In the late 1800's, Dr. William Coley noticed a marked reduction in tumor growth, and 
in some cases, tumor regression in cancer patients with streptococcal infections (41). 
Administration of killed bacteria and bacterial extracts gave similar results. In the early 1900's, 
"Coley's toxins" became an approved chemotherapeutic agent (178). The inherent danger of 
treating patients with bacterial extracts and the advent of more effective chemotherapeutics and 
radiation therapy led to the replacement of this form of chemotherapy. 
Although much effort was put into its isolation, the factor in "Coley's toxins" 
responsible for mmor regression was never found. In 1975, however, Dr. Lloyd Old's 
laboratory discovered an endotoxin-induced serum factor that caused necrosis of several 
tumors in vivo (40). In addition to coining the term "tumor necrosis factor", this paper also 
described a murine cell line, L929, that was sensitive to TNF-mediated lysis. This cell line is 
still widely used today to detect TNF bioactivity. In the early 1980's, it was discovered that 
rabbits infected with Trypanosoma brucei were stricken with anorexia and cachexia (117). 
These symptoms could be duplicated by the passive transfer of serum fi-om lipopolysaccharide 
(LPS)-treated mice to naive rabbits (116). Kawakami and Cerami called this serum factor 
"cachectin" (116). When the genes for both tumor necrosis factor and cachectin were isolated 
and sequenced, they were found to be the same molecule (20). 
Lymphotoxin was first described in 1968 as a lymphocyte derived factor that killed 
target cells (88). When the gene for human lymphotoxin was cloned and sequenced, it was 
found to be 35% homologous to mmor necrosis factor (89). This discovery led to the modem 
nomenclature of cachectin as TNFa and lymphotoxin as TNpp. For simplicity, the remainder 
of this review will refer to tumor necrosis factor alpha as TNF and mmor necrosis factor beta 
as LT. The genes for both molecules lie within the major histocompatibility complex (MHC) in 
humans (226), mice (170) and swine (224). 
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Inducing agents and sources of TNF 
The first cells known to produce TNF were LPS-stimulated monocytes and 
macrophages (178). In fact, murine TNF was originally purified and sequenced fi-om a 
macrophage-like cell line (22,247). Since the mid 1980's, several other ceU types and 
inducing agents have been discovered. T lymphocytes produce both TNF and LT (232). Pre-
B cells, B cells, and B ceU lymphomas produce LT in response to immunogloblulin (Ig) 
crosslinking and phorbol ester (PMA) stimulation (22). Neutrophils, natural killer (NK) cells, 
keratinocytes, microglial cells and certain tumor cells have all been shown to produce TNF in 
response to a wide variety of stimuli (Table 1). In addition to the many bacterial, viral and 
environmental insults resulting in TNF production, there are several cytokines that stimulate 
cells to produce TNF (Table 1), making TNF and LT a part of the pro-inflammatory cytokine 
network. 
Inhibitors of TNF production 
There are several pharmacological agents that inhibit the production or secretion of TNF 
(Table 2). Pentoxifylline, which is a phosphodiesterase inhibitor, increases the level of 
uitracellular cAMP and decreases TNF mRNA accumulation within stimulated cells (235). 
Other chemicals that increase intracellular cAMP levels have the same effect. These agents 
include cAMP analogs and activators of adenyl cyclase (113). Glucocorticoids, such as 
dexamethasone and cortisone also inhibit TNF production. Since pre-treatment is required to 
inhibit TNF production (195), it is thought that glucocorticoids act by blocking the activation 
signal required for cells to produce TNF (265), and by affecting the 3' untranslated region to 
destabilize TNF mRNA (96). In addition to inhibiting interleukin 2 (IL-2) production, 
cyclosporin inhibits the release of TNF from cells without affecting TNF mRNA accumulation 
(174, 194). Thalidomide inhibits TNF production by reducing the half-life of TNF mRNA 
(159). 
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Table 1. Cells that Produce TNF and Inducing Agents 
Cell Agent Reference 
Macrophages & Monocytes LPS (21) 
(TNF) 
LPS & (Gamma Interferon) IFNy (84) 
Zymosan (233) 
Phorbol Esters (208) 
TNFa (53) 
Interleukin 1 (IL-1) (187) 
Interleukin 2 (IL-2) (63) 
Granulocyte-macrophage colony (39) 
stimulating factor (GM-CSF) 
Viral infection (5) 
T Lymphocytes (TNF and LT) IL-2 & anti-CD3 (232) 
PMA & anti-CD3 (236) 
B Lymphocytes (TNF) PMA (237) 
Natural Killer (NK) cells IL-2 (81) 
(TNFa) 
Target Cells (185) 
Neutrophils (TNF) LPS (62) 
Candida albicans (60) 
Keratinocytes (TNF) UV exposure (124) 
Microglial cells (TNF) LPS or IL-1 (209) 
Viral infection (136) 
Tumor cells (TNF) Epithelial tumor cells (229) 
Carcinoma cells (228) 
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Table 2 Inhibitors of TNF Production 
Inhibitor Mechanism Reference 
I. Pharmacologic 
Phosphodiesterase Inhibitors Increase cAMP levels (235) 
Pentoxifylline Decrease mRNA transcription (235) 
Theophyline (235) 
Adenyl Cyclase Activators Increase cAMP levels (113) 
Cholera Toxin (113) 
Forskolin (113) 
Glucocorticoids Shorten mRNA half-life (96) 
Dexamethasone Inhibit translation (265) 
Cortisone (265) 
Cyclosporin Inhibits TNF release (174) 
Thalidomide Shorten mRNA half-life (159) 
II. Biologic 
Prostaglandin E2 (PGEj) Increase cAMP levels (129) 
Immosuppressive Cytokines 
TGFp Suppresses mRNA translation (26) 
Interleukin 10 Shortens mRNA half-life (26) 
Interleukin 4 Decreases mRNA transcription (275) 
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Drugs and hormones are not the only agents able to decrease TNF production. There 
are several factors produced during the course of an inflammatory response that down-regulate 
TNF expression. Prostaglandin E2 decreases TNF mRNA transcription by increasing 
intracellular cAMP levels. Inmiunosuppressive cytokines act as a negative feedback system to 
modulate TNF production. Neither transforming growth factor-beta (TGF-|3) nor interleukin 
10 (IL-IO) affect the rate of transcription of TNF mRNA. However, TGF-(3 suppresses its 
translation and IL-10 increases the rate of TNF mRNA degradation (26). Interleukin 4 (IL-4) 
decreases the rate of TNF mRNA transcription (275). The activity of TNF can also be 
decreased by circulating TNF binding proteins. Activated cells often shed their TNF receptors, 
rendering the target cell less sensitive to TNF and creating soluble TNF binding proteins which 
are able to inhibit TNF bioactivity (261). 
Bioactivity of TNF in vitro 
There have been numerous in vitro studies over the past decade aimed at determining 
the mechanisms behind the many physiologic alterations caused by TNF. Exposure to TNF 
dramatically changes both gene expression and morphology of endothelial cells. Cells decrease 
their fibronectin expression while increasing their expression of intercellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule (VCAM) and endothelial selectin 
(E-selectin) (42,234). These two events loosen tight junctions between endothelial cells and 
increase leukocyte adhesion to endothelial cell monolayers. In addition, TNF suppresses 
thrombomodulin synthesis and promotes blood clotting (133). Endothelial cells activated by 
TNF also produce platelet activating factor (FAF), interleukin 1 (IL-1), interleukin 6 (IL-6), 
and granulocyte-colony stimulating factor (G-CSF) (Table 3). These pro-inflammatory 
cytokines further an immune response by stimulating the production of more neutrophils, 
activating leukocytes, and attracting neutrophils and macrophages to an inflammatory site. 
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Table 3. Major Effects of TNFa Exposure on Various Cell Types 
Cells Effect Reference 
Endothelium Increased adhesion molecule expression (42) 
Decreased thromobmodulin (133) 
Increased EL-l expression (169) 
Increased G-CSF, M-CSF, GM-CSF (217) 
Increased PAF expression (38) 
Increased IL-6 expression (110) 
Separation of tight junctions (234) 
Neutrophils Increased adhesion to endothelium (77) 
Enhanced phagocytosis (141) 
Enhanced respiratory burst (123) 
Increased CR3 expression (231) 
Enhanced antimicrobial activity (60, 72, 231) 
Increased PAF production (38) 
Monocytes & Increased antigen presentation (274) 
Macrophages Increased MHC n expression (268) 
Increased Nitric Oxide and ROI (56) 
Production of IL-10, M-CSF (91, 267) 
Production of IL-I, IL-6 (28, 223) 
Antimicrobial effects (17,51, 137) 
T cells Synergy with IL-2 (212) 
B cells Enhances proliferation & maturation (108) 
Muscle cells Inhibits myoblast differentiation (153) 
Adipocytes Decreases lipoprotein lipase (273) 
Fibroblasts Increases IL-8, IL-1, G-CSF, GM-CSF (64, 213, 216) 
Inhibits collagen synthesis (112) 
Increased collagenase synthesis (32) 
Increased proliferation (85, 119) 
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Neutrophils and macrophages are the first cells to arrive at an inflammatory focus. 
These cells are also greatly affected by TNF exposure. Treatment of neutrophils with TNF 
increases their adhesion to endothelial monolayers (77), enhances their effector functions (71, 
128), and increases their antimicrobial activity (60,69,70,127). Monocytes and macrophages 
are activated by TNF, as well as being a major source of TNF. Human monocytes are rescued 
from apoptosis (148) and will move toward higher concentrations of TNF (266). They also 
produce lL-1 and IL-6 upon stimulation (28,223). Gamma interferon (IFNy) acts 
synergistically with TNF to make macrophages more efficient killers of bacteria (115,128) and 
parasites (162). 
Fibroblasts stimulated by TNF produce IL-8, G-CSF and granulocyte-macrophage 
colony stimulating factor (GM-CSF) (213). The production of G-CSF and GM-CSF promotes 
neutrophil and monocyte production from the bone marrow, while IL-8 is a potent neutrophil 
chemoattractant. Tumor necrosis factor also decreases collagen stores by inhibiting collagen 
synthesis (112) and increasing coUagenase production (32). Fibroblast proliferation is also 
stimulated by TNF exposure (15, 161). 
Effects of TNF production in vivo 
The importance of TNF production is most evident during ±e course of bacterial 
infections. The pro-inflammatory effects of endothelial and leukocyte activation serve to 
quickly mobilize neutrophils and marcophages to the site of inflammation (43,144). This 
response is particularly important in containing and eliminating intracellular pathogens, such as 
Listeria monocytogenes (37,164, 207), Salmonella spp. (151), Mycobacteria spp.(17) and 
Leishmania (95,137). Smdies have shown that pre-treatment with anti-TNF antibodies or 
soluble TNF receptors worsens disease resistance to these pathogens following challenge. 
Conversely, administration of exogenous TNF before or early during infection will improve 
the resistance of mice to infection (137, 163,165). 
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The pro-inflammatory, growth potentiating, and cytotoxic effects of TNF on fibroblasts 
make it an important part of wound healing. Following trauma, local tissue macrophages 
produce TNF, which draws more cells to the site of injury (144). Infiltrating cells produce 
TNF and other cytokines, which both activate leukocytes at the site and elicit more cells from 
circulation (59). These cells combat infection and clear away damaged tissue. In addition, 
TNF speeds wound closure by increasing fibroblast proliferation (76). These wound healing 
activities may also serve to contain chronic infections, such as Mycobacteria spp.and contribute 
to tissue re-modeUng (249). 
The pathophysiological effects of TNF overproduction have been studied in a variety of 
ways. Acute TNF exposure can be studied in vivo by the direct administration of recombinant 
TNF, by intravenous injection of lipopolysaccharide (LPS), and by neutralizing endogenous 
TNF activity by antibody or soluble receptor administration (249). One of the most well 
smdied TNF pathologies is that of septic shock. Tumor necrosis factor is thought to be a 
critical mediator of septic shock for a number of reasons. Injection of high doses of TNF 
causes most of the symptoms associated with septic shock (251, 253). Patients with gram-
negative sepsis often have extremely high levels of serum TNF (47) and patients with higher 
TNF levels tend to have higher mortality rates than those with lower TNF levels (35). When 
three different strains of mice are given a dose of TNF that would normally be seen after a 
lethal endotoxin challenge, they develop neutrophilia, lymphopenia, increased vascular 
permeability, bowel necrosis and hypovolemic shock (193). Similar results have been shown 
in dogs (2,154) and rabbits (152). Treatment of pigs (109), rodents, (220, 221) and non-
human primates (252,254) with anti-TNF antibodies prior to a lethal endotoxin challenge 
protects animals from death. Other human diseases where TNF is thought to have a negative 
impact include adult respiratory distress syndrome (ARDS) (73,214), meningitis (122,259), 
cerebral malaria (78, 128) and bum trauma (149,171). 
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Chronic exposure to TNF can also have harmful effects. Cachexia associated with 
cancer has been attributed in part to patients' chronic exposure to TNF (45,225). Chronic 
inflammation of rheumatoid arthritis has also been linked to TNF overexposure, since 
administration of anti-TNF antibodies lessens joint swelling and synovial membrane 
inflammation (146). Cachexia associated with acquired immunodeficiency syndrome (AIDS) 
is also correlated with elevated TNF levels (130,225). There is also evidence that TNF 
actually enhances viral proliferation in AIDS patients (103, 176). When low doses of TNF are 
given to rats intraperitoneally, they exhibit cachexia, severe anemia, leukocytosis, and liver and 
spleen inflammation (250). Tumors engineered to secrete human TNF grafted to the hind 
limbs of mice cause the mice to lose weight, and develop chronic cachexia (179). If a similar 
tumor is introduced into the brain, mice develop an acute anorexia (255). Mice carrying a TNF 
transgene under the control of an insulin promoter develop chronic pancreatic insulitis (188, 
203). When TNF is introduced as a transgene with a T cell specific promoter, mice develop a 
wasting syndrome, characterized by necrosis in the liver, pancreas, and lymph nodes, vascular 
thrombosis, and growth retardation (188). Other transgenic studies have shown that mice 
carrying a transgene producing T cell-bound TNF develop local T cell-mediated diseases, such 
as synovitis and chronic inflammatory arthritis (82). In each of these transgenic studies, mice 
expressing more of the transgene, also displayed more severe symptoms. These results 
indicate that the site of TNF production, as well as the amount of TNF produced is important to 
the clinical outcome of TNF exposure. 
Receptors for TNF and LT 
The cellular and systemic effects of TNF and LT are mediated by two receptors, 
TNFRl and TNFR2. These receptors bind both TNF and LT with high affinity (57). The two 
receptors have several different names: TNFRl is also called the p55 TNF receptor or TNFRP 
and TNFR2 is also called the p75 TNF receptor or TNFRa (142). The first indication that 
there are two different receptors for tumor necrosis factors was the discrepancy in the 
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molecular weight of TNF-TNFR complexes. Myeloid cells have a single class of cross-linked 
products weighing 100-105 kDa, while epitheloid cells have two major products, at 75-85 kDa 
and at 100-105 kDa (102). Monoclonal antibodies provided further evidence for the existence 
of two receptor types. A human myeloid cell line, HL-60, and a lymphoma cell line were lysed 
and the TNF binding proteins from each were affinity purified. These purified lysates were 
used to immunize mice and develop non-crossreactive monoclonal antibodies htr (anti-
TNFRl) and utr (anti-TNFR2) (33). Final proof came with the cloning and sequencing of the 
cDNAs encoding the two receptors in humans. The cDNAs for TNFRl and TNFR2 have been 
cloned in several species (Table 4). 
Table 4. Cloning of TNFRl and TNFR2 cDNAs in Different Species 
Receptor Species Source Reference 
TNFRl Human HL-60 cells (211) 
Placenta (90) 
Placenta (143) 
Colon (177) 
Murine Macrophage (135) 
T cell line (14) 
T cell line (87) 
Rat Spleen (101) 
Porcine Kidney cell line (238) 
TNFR2 Human Lung Fibroblasts (222) 
U-937 cells (125) 
HeLa2-5 cells (98) 
Murine T cell line (87) 
Macrophage (135) 
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Both TNFRl and TNFR2 have cysteine-rich extracellular domains, making them part 
of the nerve growth factor receptor (NGFR) superfamily (222). Other members of this family 
include Fas antigen (106), OX40 (147), CD27 (36) and PV-T2 (256). The extracellular 
domains of the proteins in this family share approximately 25-30% amino acid sequence 
identity, with the cytoplasmic tails of each being distinct (222). The extracellular domains of 
the two TNF receptors are approximately 28% homologous in humans and mice and have 
dissimilar cytoplasmic tails (49). 
The two TNF receptors also have different tissue distributions. TNFRl is expressed at 
low numbers (500-2000 receptors/cell) on nearly all nucleated cells (57, 138). When lymphoid 
tissues were tested by immunohistochemistry, TNFRl was detectable on dendritic reticulum 
cells in the germinal centers of tonsils, lymph nodes, spleen and mucosa-associated lymphoid 
tissue (205). The germinal centers are also the main site of TNF production in these tissues 
(206). However, TNFR2 has a more restricted tissue distribution. Most unstimulated cells 
expressing TNFR2 are of myeloid origin (33, 57). TNFRl is found at lower levels per 
individual cell, but is more abundant in a given individual (29,242). The notable exception to 
this is found in developing placenta, where the level of both TNFRl and TNFR2 is 
developmentally regulated. TNFRl is expressed at high levels throughout pregnancy. 
TNFR2, however, is only expressed intermittently during the first trimester (272). 
Receptors for TNF are subject to regulation at both the transcriptional and post-
translational levels. Before the discovery of two separate receptors for tumor necrosis factor, it 
was known that IFNy treatment increased the number of TNF binding sites on cells (6). 
Treatment with LPS has the opposite effect, decreasing the TNF receptor levels on 
macrophages (58). The expression of TNFR2 is transcriptionally regulated by both IFNy and 
LPS, with IFNy increasing and LPS decreasing the level TNFR2 mRNA in treated cells (239). 
Treatment of fibroblasts with TNF or IL-1 causes an increase in both TNFR2 mRNA levels 
and TNFR2 protein expression (270). This increase leads to an increase in the TNF-binding 
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capacity of stimulated cells as well. Monocyte and fibroblast cell lines stimulated with TNF 
show slightiy lower levels of TNFRl mRNA (138,270). All of the stimuli tested to date have 
left TNFRl mRNA transcripts unaffected or slightly reduced (138, 139,270) indicating that 
regulation of TNFRl is accomplished at a post-transcriptional level. Analysis of the TNFRl 
promoter supports this hypothesis, since the TNFRl promoter contains several motifs 
commonly seen in housekeeping genes (118,197) which are not subject to transcriptional 
regulation. 
Differential roles for TNFRl and TNFRl 
The dissimilarity between the cytoplasmic tails of TNFRl and TNFRl is an indication 
that the two receptors mediate different cellular responses. The role of each receptor has been 
studied using cells expressing either TNFRl or TNFR2 (99), using TNFRl or TNFR2 
specific antibodies to either block (antagonist) or mimic (agonist) the effects of ligand binding 
(80,240,246), stimulating cells with TNFRl- or TNFR2-specific TNF mutants (13) or by 
studying the phenotypes of TNFRl or TNFR2 deficient mice (67, 198). 
Several studies have shown that TNFRl is capable of mediating most of the effects 
atUibuted to TNF in the absence of TNFRl. These effects include cytotoxicity (13, 99, 240), 
lethal endotoxic shock (198,218), and inflammatory leukocyte infiltration into organs (173) 
(Table 5). The TNFRl-mediated induction of mitochondrial manganous superoxide dismutase 
(MnSOD) may be a direct effect of TNF exposure, or may be the result of cellular stress prior 
to cell death (240). Agonist TNFRl specific antibodies and TNF protect target ceils from viral 
cytopathology (271). Other studies demonstrate a key role for TNFRl in thymocyte and T cell 
proliferation (240, 242) as well as TNF-induced skin necrosis (218). There are several TNF-
mediated cellular responses requiring activation of both receptors, including DNA 
fnigmentation (99), neutrophil priming (13) and NK cell proliferation (168). 
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Table 5 Differential Roles of TNFRl and TNFR2 
Receptor Function Reference 
TNFRl Cytotoxicity (13, 99, 240, 243) 
Induction of manganous superoxide dismutase (240) 
(MnSOD) 
Increases MHC expression (145,246) 
Protection from viruses (271) 
Increased adhesion molecule expression on (173) 
endothelium 
Lethal endotoxic shock (186, 198,218) 
L. monocytogenes resistance (67, 186, 198) 
TNFRl Thymocyte proliferation (240) 
T cell proliferation (218, 242) 
TNF-induced skin necrosis (218) 
TNFRl &TNFR2 Mononuclear cell proliferation (80) 
DNA fragmentation (99) 
Fibroblast proliferation (34) 
Neutrophil activation (13) 
NFKB activation (126, 242) 
NK cell activation (168) 
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Both receptors have been deleted at the genetic level in mouse strains. The phenotypes 
of these mice correlate well with previous data. The TNFRl-deficient mice are resistant to 
endotoxin-induced shock and are more susceptible to Listeria monocytogenes infection than are 
wild-type mice (198) These mice fail to develop Peyer's patches, but have normal spleens and 
lymph nodes (172). Mice lacking TNFR2 are also resistant to endotoxic shock, but to a lesser 
extent than TNFRl knockout mice. The TNFR2 deficient mice have no increased sensitivity to 
L monocytogenes, and are only mildly affected by intradermal TNF injections, which cause 
tissue necrosis in wild-type mice (67). 
TNFRl and TNFR2 signal transduction 
Studies on the different roles of the two receptors for TNF and LT have led to several 
discoveries regarding the signal transduction pathways of each receptor. While the picture is 
far from complete, a great deal is known about the intracellular proteins interacting with each 
receptor upon ligand binding. Using a yeast two-hybrid system to identify proteins, Rothe and 
colleagues discovered a family of TNF receptor associated factors (TRAFs) (Figure 1) (200). 
These proteins associate with each other through conserved TRAF domains present on each 
protein and form a heterodimer of TRAF 1 and TRAF2 that binds to the cytoplasmic tail of 
TNFR2 upon receptor activation. Further studies have shown that two cellular inhibitors of 
apoptosis proteins (c-IAPs) bind to TRAF1-TRAF2 heterodimers associated with TNFR2 
(199). There is also a TRAF inhibitory protein, I-TRAF (202), that binds to TRAFs in the 
cytosol and prevents TRAF interaction with TNFR2. The mechanism by which TRAFs are 
released from I-TRAF is currently unknown, however, it is known that overexpression of I-
TRAF inhibits NFKB activation through TNFR2 (201). (Figure 1) 
There is more known about the TNFRl signaling machinery than is known about that 
of TNFR2 (Figure 2). Crystallographic analysis of LT bound to TNFRl shows that three 
receptor molecules bind to a trimeric ligand molecule (12). The cytoplasmic tail of TNFRl 
contains an eighty amino acid death domain that is required for the receptor to cause 
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cytotoxicity in target cells (241). This death domain is present in both TNFRl and Fas 
antigen, but not in TNFR2. It is highly conserved between species and between the death 
domains of TNFRl and Fas antigen. Fas antigen causes cell death upon Fas ligand binding. 
There are several cytosolic proteins that also contain similar death domains. These death 
domains interact with one another upon activation of TNFRl. Upon TNFRl trimerization, the 
death domain of TRADD (TNF receptor associated death domain) interacts with the death 
domain of TNFRl (105). 
TNF 
TNFR2 Cell membrane 
Fi! 
TRAP 
TRAFl 
I— I-TRAF 
I Ic-IAP Activation of: 
Kinases 
Cell proliferation 
9 
Figure 1. Signal Transduction Through TNFR2. 
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The TRADD protein has a death domain on its carboxyl end and a TRAF domain at its 
amino end. These two domains of TRADD may bind to other cytoplasmic factors, mediating 
distinct cellular activities. The death domain of TRADD may interact with both TNFRl and 
FADD (Fas associated death domain). If TRADD binds to FADD, FADD binds to MACH 
(MORT-1 associated ced-3 homolog) via its death effector domain (DED). MACH is a 
protease required for TNFRl or Fas-mediated apoptosis (27) that has a similar DED. The 
TRAF domain of TRADD may form a heterodimer with with TRAK, which is similar to the 
TRAF1-TRAF2 heterodimer formed in TNFR2 signaling (104). If TRADD interacts with 
TRAF2, both TRAF2 and c-IAPl are brought to the TNFRl signaling complex (219). Several 
kinases, including IKB kinase and Jun-N-terminal kinases (JNK), are activated in a TRAF2-
dependent pathway (140, 166) (Figure 2). 
The two pathways downstream of TRADD seem to be mumally exclusive. The TRAF2 
association leads to kinase and transcription factor activation (104). Activation of NFKB in 
particular prevents apoptosis (140), as does overexpression of c-IAPl (219). The shared 
cytoplasmic factor TRAF2, may explain the shared cellular responses of TNFRl and TNFR2 
(Table 5). The indirect interaction of TNFRl with FADD, may also explain some of the 
similarities between TNF and Fas-mediated apoptosis. 
Shedding of TNF receptors 
The receptors for TNF and LT can be proteolytically cleaved and released from cell 
surfaces. These receptors retain their ability to bind TNF and LT and enter circulation as TNF 
binding proteins. These soluble receptors were originally purified as TNF inhibitors from 
urine (65,215) and serum (3,79). These purified proteins were identified as the extracellular 
domains of TNFRl and TNFR2 (66,261) and have been used to protect non-human primates 
from lethal endotoxemia (261). 
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19 
Since the discovery of soluble receptors for TNF and LT, several groups have 
investigated many aspects of receptor shedding. While normal subjects have low or 
undetectable levels of circulating sTNFR, injection of human volunteers with sublethal doses 
of endotoxin causes a rapid rise and fall of TNF levels, followed by a similar peak of sTNFRl 
and a gradual, more sustained, rise in sTNFR2 (227,261). If mice are treated with TNF, a 
similar rise in circulating sTNFR levels is seen (16). There may also be a role for IFNy in 
regulating receptor shedding in vivo, since mice treated with blocking antibodies against IFNy 
prior to LPS administration have higher TNFR2 levels, but lower TNFRl levels than control 
mice treated with LPS alone (16). 
The major cellular sources for these soluble receptors are thought to be neutrophils, 
monocytes and T lymphocytes. Neutrophils incubated with GM-CSF, phorbol esters, or 
fMet-Leu-Phe (fMLP) have significantly fewer TNF-binding sites per cell than unstimulated 
neutrophils. Stimulation of human neutrophils with fMLP, which causes the greatest decrease 
in TNF receptor levels, also results in a marked increase in TNF binding activity in culture 
supematants, indicating that TNF receptors were shed from cells and not internalized (192). 
Elastase, a component of neutrophil azurophilic granules, selectively releases TNFR2 from 
neutrophils, which are thought to be the major source for sTNFR2 in vivo (57,190). 
Stimulation with TNF also induces TNFR2, but not TNFRl release from neutrophils (191). 
Monocytes are also a significant source of soluble TNF receptors in vivo. In contrast 
to neutrophils, which rapidly shed their TNFR2 upon activation, monocytes slowly release 
both TNFRl and TNFR2 when stimulated with phorbol esters (132) or LPS (131). 
Interleukin 10, an anti-inflammatory cytokine produced by monocytes and other cells, 
increases shedding of both TNFRl and TNFR2 from monocytes (111, 132). Surprisingly, the 
pro-infianmiatory cytokines TNF and IFNy have no effect on monocyte TNF receptor 
shedding (132), and interleukin 4, which is an anti-inflammatory cytokine, decreases receptor 
shedding by monocytes (111). Stimulated T cells produce mostly sTNFR2 upon acute 
20 
exposure to TNF. Chronic TNF exposure, however, suppresses sTNFR2 production by T 
cells (44). 
Several studies have been done on the molecular mechanisms of TNF receptor 
shedding, particularly the mechanisms behind TNFRl release. There is a requirement for an 
asparagine and valine amino acid pair at positions 172 and 173 (human TNFRl numbering 
(l(X)))near the transmembrane domain for cleavage of TNFRl from cells' surfaces (92). 
Mutation of either site reduces shedding by approximately 50%. Mutation of both nearly 
eliminates cleavage and release of TNFR1(92). The presence and site of these two amino acids 
is conserved in human (90), mouse (135), and rat (100) TNFRl. If the cytoplasmic tail of 
human TNFRl is deleted, signaling (cell death) does not occur, but shedding of the receptor 
does, indicating that receptor cleavage is not dependent upon receptor activation (30). 
The proteases responsible for the cleavage of TNFRl and TNFR2 have not yet been 
identified. However, several advances have been made in the last few years. Elastase can 
cleave TNFR2 from the surface of neutrophils, but does not cause the same level of receptor 
shedding as does neutrophil activation (190). Several protease inhibitors, such as trypsin 
inhibitor, pepstatin, and diisopropylfluorophosphate (DFP) have no effect on TNF receptor 
shedding from neutrophils (192). However, it has been recentiy reported that metalloprotease 
and serine protease inhibitors can block both TNFRl (160) and TNFR2 (24,46) shedding. 
These advances have led to the isolation of an inducible protease found in a T cell line 
(THP-1), capable of cleaving TNFR2. Like elastase, however, this protease does not have the 
same level of activity as activated cells (114). 
Bioactivity of soluble TNF receptors 
Since their discovery as TNF inhibitors, soluble TNF receptors have been tested both 
in vitro and in vivo for their ability to block TNF-mediated effects. Recombinant (E. coli 
derived) and native (purified from urine or PMA stimulated U937 cells) sTNFR are able to 
block both TNF binding to human U937 cells and TNF-mediated cytotoxicity to murine L929 
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cells (94). There is no difference between native and recombinant protein activity in either of 
these assays. Baculovirus derived recombinant soluble TNFRl has a Kd of 0.38 nM for 
TNFa. Cells treated with tunicamycin to prevent glycosylation of expressed proteins produced 
recombinant human TNFRI that boimd TNF as well as the fully glycosylated recombinant 
protein (142). 
While glycosylation does not seem to affect binding of rsTNFRl or rsTNFR2 to TNF 
or inhibition of binding activity, there is a substantial difference in serum half-life of Chinese 
hampster ovary (CHO) cell derived rsTNFRl and E. coli derived rsTNFRl. The clearance of 
intravenously injected sTNFR from the bloodstream of mice takes place in two phases. During 
the initial phase (T,/,^), substantial amounts of the TNF-Rs are cleared within minutes of 
injection. Recombinant soluble TNF receptors surviving the initial clearance are eliminated at a 
slower rate (T,/2p). E. coli derived protein is quickly eliminated from circulation, with only 1% 
of the injected (IV) dose remaining 18 minutes after injection. The CHO cell derived protein, 
however, is cleared at a much slower rate. Initial clearance eliminates 62% of the injected dose 
from circulation in 58 minutes. The remaining 38% is cleared in a second phase, with a T,/,^ 
of 3.8 hours (107). 
The serum half-life of TNFR can be further extended by the constraction of TNFR-Ig 
fusion proteins which consist of the extracellular, ligand binding domain of either receptor, and 
the Fc portion of human IgG. When such a construct is injected intravenously into mice, only 
39% of the fusion protein is cleared from circulation in the initial phase lasting 26 minutes. 
More importantly, the T,y2p of the fusion protein is 20 hours, in contrast to the 2-4 
hours for recombinant soluble TNF receptors (107). Others have reported a serum half-life of 
these fusion proteins at between one and six days (93, 134). 
In addition to greater serum half-life, TNF receptor-Ig fusion proteins, or 
immunoadhesins also have a greater binding capacity for TNF. This is generally attributed to 
their bivalence, which leads to greater avidity (134). This increased binding capacity of 
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immunoadhesins makes them more efficient inhibitors of TNF both in vitro and in vivo. 
Studies have shown TNFRl immunoadhesins are twenty-four times more effective than 
recombinant soluble TNFRl and four times more effective than anti-TNF antibodies at 
blocking TNF mediated lysis of murine LM cells (9, 184). A TNFR2 immunoadhesin inhibits 
TNF-mediated cytotoxicity at a concentration lOOOx less than that required for sTNFR2 to have 
the same effect (155). In a separate study, a TNFRl immunoadhesin was shown to be 10-50 
times more effective than anti-TNF antibodies and 500 times more effective than soluble 
TNFRl at blocking TNF-mediated lysis of LM cells (93). 
Both sTNFR and sTNFR immunoadhesins have been used in vivo, to prevent the 
detrimental effects of TNF overproduction. Both TNFRl and TNFR2 immunoadhesins are 
able to prevent exacerbation of relapsing-remitting murine experimental allergic 
encephalomyelitis (11). Repeated administration of a TNFR2 immunoadhesin prevents runting 
in mice carrying a TNF transgene or a TNF-producing tumor (244). Both recombinant soluble 
TNFR2 and a sTNFR2 immunoadhesin are able to inhibit TNF-induced human 
immunodeficiency virus (HIV) activation in monocyte and lymphocyte cell lines (103). 
The effectiveness of TNFRl immunoadhesins in comparison to TNFR2 
immunoadhesins has been the subject of intense smdy in recent years. Soluble TNFRl is ten 
times more effective than sTNFR2 at blocking TNF-mediated cytotoxicity of target cells (261). 
In a comprehensive in vivo study measuring the ability of rsTNFRl or rsTNFR2 to inhibit 
TNF-induced neutrophil influx, serum IL-6 increases, and TNF-induced shock. Hale and 
colleagues found that sTNFRl was 5-30 times more effective than sTNFR2 at blocking these 
effects (94). Not surprisingly, sTNFRl inmaunoadhesins appear to be more effective at 
protecting mice from lethal endotoxic shock (155,210). When mice are injected intravenously 
with live E. coli, the TNFRl inmiunoadhesin protects mice from lethal sepsis. However, 
when given as much as five times more TNFR2 immunoadhesin, death from septicemia is 
merely delayed (68). The current opinion is that sTNFR or sTNFR immunoadhesins can act as 
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either inhibitors or carriers of TNF, depending on relative receptor-ligand concentrations. At 
low TNF concentrations, soluble TNF receptors tend to stabilize the trimeric structure of TNF, 
thereby preserving its bioactivity (4,155). At higher TNF concentrations, soluble TNF 
receptors and their iminunoadhesins block TNF activity (68). 
Soluble TNF receptors in disease 
Experimental endotoxemia is not the only condition that causes a rise in sTNFR levels. 
Normal human subjects have low to undetectable levels of circulating sTNFRl or sTNFR2 (3). 
Gram negative sepsis (183, 258), cerebral malaria (120) and HIV infection (86) are examples 
of diseases that cause a dramatic rise in serum sTNFR levels in humans. In these and several 
other conditions (Table 6), higher levels of both sTNFRl or sTNFR2 are associated with 
worsened morbidity and mortality rates (54). Measurable circulating soluble TNF receptor 
levels have predictive value in cancer and transplant patients as well (50,55). While the 
presence of these receptors seems to be a symptom rather than a cause of disease progression, 
they provide a good indicator of immune activation, especially in conditions known to cause a 
rise in TNF levels. 
Table 6. Conditions with a negative correlation between soluble TNF receptor 
levels and prognosis. 
Condition Reference 
Bacterial sepsis (156, 245, 258) 
Typhoid Fever (121) 
Meningitis (157, 204, 260) 
Cerebral Malaria (48, 158) 
HIV Infection (23, 196) 
Rheumatoid Arthritis (31,97) 
Cancer (52, 55, 264) 
Transplantation (50, 61, 189) 
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Use for studying TNFRl in swine 
Preliminary studies using soluble TNF receptors and receptor immunoadhesins to 
protect mice (9,68, 94), pigs (269), and non human primates (261,262) from endotoxemia 
and gram-negative sepsis have been promising. A recent human trial involving 141 septic 
patients, however, did not yield positive results. Patients in the treatment groups (high and 
low dose TNFR2 immunoadhesin) acmally had a higher mortality rate than patients in the 
placebo group (75). Other clinical trials using anti-TNF antibodies to treat sepsis met with 
similar results (1). Further hiunan trials utilizing either TNF receptor immunoadhesins or 
monoclonal antibodies have been postponed or canceled (83). 
The promising results of animal smdies followed by the disappointing human clinical 
trials indicate that further animal experimentation is needed prior to further human testing. 
Swine are a commonly used experimental model for endotoxemia, sepsis and ARDS (25, 109, 
175, 180). Their size allows for measurement of respiratory and circulatory parameters that are 
not possible with mice or other rodents (74). Pigs are also similar to humans in that both 
species are extremely sensitive to endotoxin (181). Mice and rabbits, however are relatively 
resistant, requiring mg/kg doses of endotoxin to elicit the same response seen with Hg/kg doses 
given to humans or pigs (181). In order to fully utilize the swine model, however, more 
swine-specific reagents are needed. The interactions between TNF and its receptors are 
species-specific (135,182) and human or murine anti-TNF receptor antibodies are not cross-
reactive to porcine TNFRl or TNFR2. 
Aside from their usefulness as a model for human disease, there are other reasons to 
study the porcine TNF and TNF receptor system. Several pig diseases are associated with 
increased levels of circulating TNF or a tissue-specific increased incidence of TNF producing 
cells. Lungs of pigs infected withActinobacillus pleuropneumoniae have significantiy higher 
levels of TNF mRNA, by Northern blot analysis and more cells expressing TNF when 
detected by in situ hybridization (10). Mycoplasma hyopneumonia infection stimulates lung 
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TNF production as well (8). Pigs infected with Pseudomonas aeruginosa (180), £. coli (163). 
or Salmonella choleraesuisi230) have significantly higher levels of serum TNF. The role of 
TNF in Salmonella infection may be either beneficial (167) or harmful (150). There may also 
be a role for TNF in the pathology of Eschericia coli infection, since TNF exposure increases 
endothelial cell expression of receptors for Shiga-like toxin (257). It is also possible that TNF 
is part of a healthy immune response to these pathogens and required for disease resistance 
(115). The development of assays to accurately measure TNF in semm as well as the 
development of recombinant soluble TNFRl is necessary to better understand the role of TNF 
and its receptor in porcine disease and to better use swine as a model for human disease. 
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COMPARISON OF THE PK(15) AND WEHI 164 (CLONE 13) BASED 
BIOASSAYS FOR THE DETECTION OF PORCINE TUMOR NECROSIS 
FACTOR 
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Nancy Maroushek Boury, MS, Thomas J. Stabel, PhD, Marcus Kehrli, Jr., DVM, PhD, and 
Michael Taylor, MA, Vet.MB, MRCVS, D. Phil.' 
Abstract 
Objective-- To determine the relative sensitivities of the PK(15) and WEHI 164(13) based 
bioassays for the detection of tumor necrosis factor a (TNF). 
Sample Population— Recombinant human, murine, and porcine TNF as well as serum from 
endotoxin challenged pigs. 
Procedure- Two cell lines were used as targets for recombinant human, murine and porcine 
TNF cytotoxicity bioassays. Pigs were challenged with sublethal doses of endotoxin to obtain 
porcine serum samples containing high levels of porcine TNF. Serum TNF activity was tested 
using both cell lines. Viable cells were detected with dimethylthiazol diphenyltetrazolium 
bromide (MTT) after 18-20 hours of incubation with samples containing TNF. 
Results- The two cell lines tested had different sensitivities to human, murine, and porcine 
TNF. When compared with WEHI 164(13) cells, PK(I5) cells were fifty times less sensitive 
to murine TNF and fifteen times less sensitive to human TNF. However, PK(15) cells were 
four times more sensitive to recombinant porcine TNF and fifteen times more sensitive to 
porcine serum containing TNF. 
' From the Department of Veterinary Physiology and Pharmacology, Program of Molecular, 
Cellular, and Developmental Biology, Iowa State University, Ames, lA 50011 (Maroushek 
Boury, Taylor), Enteric Diseases and Food Safety Research Unit (Stabel) and Metabolic 
Diseases and Immunology Research Unit (Kehrli), National Animal Disease Center, USDA-
ARS, Ames, lA 50010. 
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Conclusions-- The PK(15) cell line was more sensitive to porcine TNF-mediated lysis than 
was the WEHI 164(13) cell line. The PK(15) based TNF bioassay will be especially useful in 
the study of infectious disease processes in swine, particularly where low levels of TNF are 
present. 
Introduction 
Tumor necrosis factor a (TNF) is a pro-inflammatory cytokine that contributes to 
resistance to many intracellular pathogens, such as Salmonella typhimuriwn ^ and Listeria 
monocytogenes?' ^ Excessive amounts of TNF, however, can be detrimental. Animals 
chronically exposed to low doses of TNF develop cachexia.^' ^ Acute, high dose exposure to 
TNF, as seen in sepsis, leads to shock and often death.'^- ^ Several pathogens responsible for 
swine diseases such as Mycoplasma hyopneumoniae,^ Actinobacillus pleuropneumoniae^^ 
and Escherichia coli induce TNF expression in vivo. Swine are also widely used as a model 
for human diseases, including septic shock,^' ^2 adult respiratory distress syndrome 
(ARDS).12 Since the amount of circulating TNF is important to the outcome of disease or 
trauma,^ the ability to detect small amounts of TNF is also important. 
Two of the most commonly used methods to measure TNF are the immunoassay and the 
bioassay. Immunoassays measure both biologically inactive and active forms of TNF. 
These assays are subject to variability due to antigenic differences between native proteins in 
test samples and recombinant standards^^- between bound and unbound TNF^"' and 
between active trimeric and inactive monomeric TNF. Bioassays rely on the ability of TNF 
to lyse a target cell line and as such, measure only biologically active TNF in samples. They 
do not measure TNF that has been denatured, bound by soluble receptors, or otherwise 
inactivated. While the sensitivity of an immunoassay is dependent upon the ability of 
antibodies to bind to TNF, the sensitivity of a bioassay is determined by the sensitivity of a 
given target cell line to TNF-mediated lysis. 
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The most commonly used cell lines for the detection of TNF are the L929 cell line and 
various clones of the WEHI164 cell line, which are murine in origin. The ability of cell lines 
to detect TNF from different species is variable.'8.19 The L929 cells were the first widely 
used target cell line.^O- 2i \ WEHI 164 subclone, clone 13, (WEHI 164(13)) has been 
reported to be lOOx more sensitive to human TNF-mediated lysis than are L929 cells.22 
Recently, Pauli et al. developed a bioassay based on a porcine kidney ceU line, PK(15), which 
they reported is lOO-lOOOx more sensitive to porcine TNF-mediated lysis than was the L929 
cell line.^ 
The purpose of this study was to determine the relative sensitivities of the PK(15) cell 
line and the WEHI 164(13) cell line. To do so, we have compared the dose-response curves of 
recombinant human, murine, and porcine TNF using both cell lines. We have also tested 
serum from S. typhimuriion endotoxin challenged pigs to determine the suitability of each cell 
line for use in testing porcine serum samples. 
Materials and Methods 
Cell lines and media 
PK(I5)'' cells were maintained at low passage number (5-30) in Eagle's Minimal 
Essential Medium (EMEM) supplemented with 5% fetal bovine serum (FBS) and 50 |ig/ml 
gentamicin. WEHI 164(13)'' cells22 were grown in RPMI-1640 (RPMI) medium with 10% 
FBS and 50 ng/ml gentamicin added. 
TNF assays 
The cytotoxicity assays were performed as previously described.23 For assays, 
PK(15) and WEHI 164(13) cells were washed m EMEM and RPMI respectively. Cells were 
diluted to 2.5 x 10^ cells/ml and added to 96 well plates at 100 |il per well. Plates were 
incubated overnight at 37 °C, 5% C02- The media was aspirated from both cell lines and 
replaced with 100 |il per well fresh RPMI (WEHI) or Iscove's medium with 0.5% 
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bactopeptone and 3 p,g/ml actinomycin D (PK(15)). Plates were incubated at 37 °C, 5% CO9 
for two hours. Samples containing TNF were diluted in RPMI (WEHI164 (13)) or Iscove's 
medium with 0.5% bactopeptone and 3 |i,g/ml actinomycin D (PK(15) and added at 50 |il per 
well in triplicate. Plates were then incubated at 39 °C, 5% CO2 for 18-20 hours. Media was 
aspirated from both sets of plates before the addition of 100 ^il per well dimethylthiazol 
diphenyltetrazolium bromide (M i l ) at 1 mg/ml in phosphate buffered saline (PBS). Plates 
were then incubated for 2 hours at 37 °C, 5% CO2 . The liquid was aspirated and 100 nl 
lysis solution (36 mM HCl in isopropanol) was added per well, which lysed cells and 
solubilized Mi l crystals. Plates were then shaken and absorbances measured at 570 nm using 
a microplate reader. Final values were corrected for background absorbance by subtracting the 
absorbance of cells lysed with distilled water prior to the addition of MTT. Percent cytotoxicity 
was calculated with the following equation: 
A57o(No TNFa Added) - A57o(Test) 
% Cytotoxicity = ———————————————— x 100 
AjvoCNo TNFa Added) 
Two-fold serial dilutions of recombmant human and murine TNF were tested at 
concentrations from 0.002 pg/ml to 250 pg/ml. Each concentration was tested in triplicate for 
each experiment. 
Porcine TNF pur^cation 
Recombinant porcine TNF was purified as previously described.Briefly, E coli 
strain LL308 that had been transformed with a pFLAG-1 plasmid expressing a pFLAG-pTNF 
fusion protein"* was grown to log phase before gene expression was induced with 0.5 mM 
isopropyl-P-D-thiogalactoside (IPTG). Cultures were grown for 5 hours at 30 °C following 
the addition of IPTG. Bacteria were lysed by four freeze-thaw cycles and the lysates were 
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cleared by centrifugation. The recombinant TNF was purified by affinity chromatography 
using an anti-FLAG MAb (Ml) column®. The purity of each preparation was verified by SDS-
PAGE and Westem blot, using Ml to detect the FLAG-TNF fusion protein. Protein 
concentration of the purified product was determined by its absorbance at 280 and 260 nm.^ 
Endotoxin preparation 
Salmonella typhimurium x4232 endotoxin was extracted by the use of a butanol-water 
method26 and lyophilized. Endotoxin was weighed and rehydrated with sterile pyrogen-firee 
saline for injection. 
Animals 
Crossbred pigs and rabbits were maintained at the National Animal Disease Center 
(NADC) in accordance with American Association for Accreditation of Laboratory Animal Care 
guidelines. Pigs weighed 75-80 kg at the time of experimental procedures. All animal 
procedures were approved by the National Animal Disease Center's Animal Care and Use 
Committee. 
Preparation of clinical sera 
In order to test the suitability of PK(15) and WEHI 164(13) cells to detect native porcine 
TNF, we injected pigs intramuscularly with a sedative mixture of 1.3 mg/kg xylazine, 2.7 
mg/kg ketamine and 2.0 mg/kg tiletamine zolazepam. Once pigs were sedated, they were 
injected intravenously with 5 or 10 ^ig S typhimurium ^4232 endotoxin per kg body weight. 
Serum was collected before endotoxin challenge and after challenge every 30 minutes for 3.5 
hours and every hour for two additional hours. Sera were fi-ozen at -20 °C. These sera were 
tested three times in both the PK(15) and WEHI 164(13) based bioassays. Five-fold serial 
dilutions of serum containing peak TNF levels were used to determine the relative sensitivity of 
PK(15) and WEHI 164(13) to porcine TNF mediated lysis. 
Preparation ofanti-TNF antisera 
Rabbits were immunized as previously described.-^ Briefly, rabbits were anesthestized 
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with xylazine (3.5mg/kg) and ketamine (30 mg/kg) injected intramuscularly. Recombinant 
porcine TNF was diluted 1:1 in Freund's Incomplete Adjuvant (FIA) and emulsified. Pre-
immune serum was collected prior to ±e first immunization. Two rabbits were injected 
subcutaneously with 600-700 jig recombinant porcine TNF for the first immunization. The 
animals were boosted with a subcutaneous injection of 600-700 ^.g protein in FIA three weeks 
later. A final boost of 1.4-1.5 mg TNF per rabbit was administered subcutaneously 9 to 12 
weeks after the second immunization. Ten days to two weeks after the final boost, rabbits 
were anethestized as above and anti-TNF antisera was collected via heart puncture. Activity of 
serum was verified by direct ELIS A using recombinant porcine TNF as a test antigen. 
Statistical analysis 
Each sample was tested in triplicate and each experiment was performed three times. Data 
from each experiment were pooled. Means of both the PK(15) and WEHI 164(13) data were 
compared using an analysis of variance (ANOVA) procedure on SAS.^s 
Results 
The two cell lines responded differentiy to recombinant TNF. The WEHI 164(13) cells 
were considerably more responsive to human TNF-mediated lysis than were PK(15) cells 
(Fig. 1). The concentration of human TNF producing 50% cytotoxicity in target WEHI 
164(13) cells (CD5Q) was 7.2 pg/ml. However, the equivalent CD50 concentration for 
PK(15) cells was 108 pg/ml, indicating that WEHI 164(13) cells were approximately 15 times 
more sensitive to human TNF than were PK(15) cells. 
The WEHI 164(13) cells were also more sensitive than PK(15) cells when testing 
recombinant murine TNF. As shown in Fig 2, the CD50 concentration of murine TNF was 
50.1 pg/ml for PK(15) cells, but only 1.07 pg/ml for WEHI 164 (13) cells. Thus, the murine 
WEHI 164(13) cells were 50 times more sensitive to murine TNF than were the porcine 
PK(15) cells. 
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The CD50 dose of recombinant porcine TNF was 6.6 ng/ml for the PK(15) cell line 
(Fig 3). The CD50 dose using WEHI 164(13) cells was 24.4 ng/ml, indicating that PK(15) 
cells were approximately 4 times more sensitive to recombinant porcine TNF than were WEHI 
164 (13) cells. The FLAG-pTNF fijsion protein has been reported to have the same activity as 
TNF alone.24.29 Our preparation had activity comparable to that of published results 
(2.1 X 10^ U/mg vs. 2.5 x 10^ U/mg) reported by Su et al., with 1 U being able to lyse 50% 
of target WEHI 164(13) cells.24 
Serum from pigs injected intravenously with 5. typhimurium ^4232 endotoxin at a 
dose of 5 or 10 Hg/kg body weight was also tested for TNF bioactivity using both cell lines. 
As previously reported,30 a rapid rise in serum TNF levels occurred at 1.5 hours after 
endotoxin injection (5 and 10 jig/kg). This serum TNF activity was detectable using both 
PK(15) and WEHI 164(13) cells. However, the PK(15) cells were consistently more 
sensitive to lysis at each time point tested (Fig 4). The means of the two lines are different 
(p < 0.0001). The peak of WEHI 164(13) cell cytotoxicity was 50.4% at 1.5 hours after 
endotoxin treatment (10 |xg/kg). The same serum sample caused 80.2% cytotoxicity in the 
PK(15) cells. When the lower dose of endotoxin was used (5 |J.g/kg), similar TNF kinetics 
occurred, with peak TNF levels being reached at 1.5 hours after injection. This peak 
corresponded to 65% cytotoxicity in the WEHI 164(13) cells and 78% cytotoxicity in the 
PK(15) ceUs. 
In order to more accurately compare the sensitivities of the two cell lines, we diluted 
serum from the 1.5 hour post endotoxin injection (10 M-g/kg) and tested serial five-fold 
dilutions using both cell lines (Fig 5). The serum dilution that caused 50% cytotoxicity in the 
PK(15) cells was 1 x 10"^. The equivalent dilution causing 50% cytotoxicity of WEHI 
164(13) cells was 1.6 x 10'^, indicating that PK(15) cells were 15 times more sensitive to 
porcine TNF in serum samples. The cytotoxic effect of these sera was blocked by the addition 
of anti-TNF antiserum (Fig 6), indicating that cytotoxicity was specific to TNF. 
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Discussion 
The murine WEHI 164(13) ceil line was more sensitive to lysis by both murine and 
human TNF than was the PK(15) cell line. The greater sensitivity of WEHI 164(13) cells to 
murine TNF was not surprising, since receptors for TNF are species specific^' and human 
TNF binds more strongly to human cells than to murine cells.The murine cells' greater 
sensitivity to human TNF was unexpected since human and porcine TNF share a greater 
sequence homology than human and murine TNF at both the amino acid and genetic level. We 
expected that porcine PK(15) cells would detect human TNF as well as or better than the 
murine WEHI 164(13) cells. Other researchers^^ have reported that the PK(15) cell line could 
detect human TNF as well as L929 cells. Espevik and Nissen-Meyer also showed that the 
WEHI 164(13) cells were more sensitive to human TNF than were L929 cells.22 in a separate 
study, PK(15) cells and L929 cells showed equivalent sensitivity to recombinant human 
TNF,23 which would indicate that they are less sensitive to human TNF than are WEHI 
164(13) cells. This conclusion is supported by our results (Fig 1), showing that WEHI 
164(13) cells were significantiy (p < 0.0001) more sensitive to TNF-mediated lysis than were 
PK(15) cells. The greater sensitivity of WEHI 164(13) cells to human TNF is likely due to the 
fact that they were subcloned from a parental WEHI 164 line and selected on the basis of their 
sensitivity to human monocyte-derived TNF.22 
Porcine PK(15) cells were more sensitive to porcine TNF-mediated lysis than were the 
murine ceUs, WEHI 164(13). While we did not observe the 100 or 1000-fold increase 
reported when Bertoni, et al.^ compared PK(15) cells with murine L929 cells, we did see a 
modest (4-fold), but significant (p < 0.0001) increase in sensitivity when testing recombinant 
porcine TNF. We saw a much greater difference (15-fold) when we tested porcine serum 
samples containing TNF. Antibodies against porcine TNF were able to block the cytotoxic 
activity of these serum samples, indicating that the differences between these two cell lines 
were due to the specific action of TNF. The greater difference in sensitivities seen in porcine 
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seram may be due to serum factors that synergize with TNF, such as interferons,^®- ^2.33 
interleukin-p2 or due to structural differences in the recombinant and native forms of porcine 
TNF. 
There are several possible reasons for the differences in the human and murine standard 
curves, measured in pg/ml and the porcine standard curve, measured in ng/ml. First, the 
difference may be an artifact of recombinant protein production and purification. There is the 
possibility that our preparation methods caused the porcine TNF to lose activity. This does not 
seem likely, however, since our protein has activity nearly equal to that originally reported. 
More likely explanations are the inaccuracy of the method of protein determination,^^ or the 
possibility that the prokaiyotically expressed FLAG-TNF fiision protein is not as active as 
eukaryotically expressed porcine TNF. While it has been reported that the FLAG-pTNF fusion 
protein had equivalent bioactivity to the TNF after FLAG had been removed, it was not 
determined whether the cleaved TNF was able to form active trimeric molecules with the 
efficiency seen in native TNF.24.34 Even after enterokinase cleavage, an extra lysine and 
leucine from the vector remains fused to the N-terminus of the recombinant TNF when using 
the FLAG purification system. These extra amino acids may make the formation of TNF 
trimers less efficient, thereby decreasing the bioactivity of the protein.^ When recombinant 
porcine TNF was originally used to test PK(15) cells for use in a bioassay ^ 9,23 researchers 
used eukaryotically expressed TNF, which may be more active than the prokaryotically 
expressed protein. 
In summary, we present evidence that the PK(15) cell line is more sensitive than the 
WEHI 164(13) cell line when used in bioassays to measure TNF level in porcine serum. 
While the WEHI 164 (13) cell line was more sensitive to human and murine TNF, low levels 
of TNF that were not detectable in the WEHI 164(13) bioassay were detectable using a 
PK(15)-based bioassay. This increased sensitivity will be particularly important when 
investigating conditions in which serum TNF levels are low . Moreover, the PK(15) bioassay 
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can be used to better understand the kinetics of TNF production in disease. 
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Figvire 1 — Human TNF Standard Curves. Recombinant human TNF (100 ^il/well) was added 
to PK(15) or WEHI 164(13) cells at concentrations from 250 to 0.061 pg/ml. Each dilution 
was tested in triplicate for each assay. Data points are the means of four assays. The means of 
the two lines are significantly different (* = p < 0.(XX)1). 
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Figure 2 ~ Murine TNF Standard Curves. Recombinant murine TNF was added (100 
|ji/well) to PK(15) or WEHI 164(13) cells at concentrations from 250 to 0.061 pg/ml. Each 
dilution was tested in triplicate for each assay. Data points are the means of four assays. The 
means of the lines are significantly different (* = p < 0.0(X)1). 
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Figure 3 — Porcine TNF Standard Curves. Recombinant porcine TNF was added (100 
^il/well) to either PK(15) or WEHI 164(13) cells at concentrations from 450 to 0.106 ng/ml. 
Each dilution was tested in triplicate for each assay. Data points are the means of three assays. 
The means of the lines are different (* = p < 0.0001). 
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Figure 4 - S typhimurium Endotoxin Time Course 5 [ig/kg (A) and 10 Hg/kg (B). Serum 
samples were taken every thirty minutes from the time of endotoxin injection to 3.5 hours after 
challenge, and again at 4.5 hours. Prior to testing, serum samples were diluted 1:250 in either 
Iscove's (PK(15) cells) or RPMI (WEHI 164(13) cells) and 100 ml/well was added in triplicate 
for each time point. Data points are the means of three assays. The means of the lines are 
different (* = p < 0.0001). 
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Figure 5 - Serial Dilutions of Peak TNF Sera. Cytotoxic activity from five-fold serial 
dilutions of serum drawn 1.5 hours after endotoxin challenge (10 pig/kg) was tested with the 
WEHI 164(13) and PK(15) cells. Each point represents the mean of three assays. The means 
of the lines are significantly different (* = p < 0.(XX)1). 
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Figure 6 — Ablation of Cytotoxic Activity by anti-TNF Antisera. A 1:50 dilution of either pre-
immune (closed symbols) or rabbit anti-porcine TNF antisera (open symbols) was added to 
serial dilutions of serum drawn 1.5 hours after endotoxic challenge (10 |J.g/kg). These samples 
were tested for cytotoxic activity against both PK(15) (squares) and WEHI 164(13) (circles) 
cell lines. 
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CLONING OF PORCINE TUMOR NECROSIS FACTOR (TNF) RECEPTOR 
AND EXPRESSION OF A RECOMBINANT, SOLUBLE TNF-BINDING 
PROTEIN. 
A paper to be submitted to the American Journal of Veterinary Research 
Nancy Maroushek Boury, MS, Brad T Bosworth, DVM, PhD, Thomas J Stabel, PhD, Marcus 
E KehrU Jr, DVM, PhD, and Michael J Taylor, MA, Vet. MB, MRCVS, D. Phil.' 
Abstract 
Objective-- The objectives of this study were to clone, sequence and express porcine soluble 
tumor necrosis factor receptor I (sTNFRl) and to determine the bioactivity of recombinant 
porcine sTNFRl. 
Procedure— A PCR-based library enrichment technique was used to isolate a fragment of 
porcine TNFRl. The mature extracellular domain of porcine TNFRl was subcloned into an 
expression vector and expressed in Escherichia coli as a FLAG fusion protein. An anti-FLAG 
affinity colurmi was used to purify the fusion protein. The bioactivity of the purified protein 
was tested for its ability to inhibit TNF-mediated cytotoxicity in a PK(15) bioassay. 
Results- A 927 bp fragment of porcine TNFRl encoding the entire extracellular and 
transmembrane domains as well as 75 amino acids of the cytoplasmic domain was isolated 
from a lung cDNA library. The mature extracellular domain was expressed as a soluble 
TNFRl fusion protein with a yield of 120-150 ng per liter of culture. Affinity purified porcine 
sTNFRl was able to inhibit TNF-mediated cytotoxicity of a porcine PK(15) cells in a dose 
dependent manner. 
' From the Department of Veterinary Physiology and Pharmacology, College of Veterinary 
Medicine, Iowa State University, Ames, LA 50011 (Maroushek Boury, Taylor); Enteric 
Diseases and Food Safety (Bosworth, Stabel), and Metabolic Diseases and Immunology 
(Kehrli) Research Units, National Animal Disease Center, ARS-USDA, Ames, lA 50010 
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Conclusions-- Porcine recombinant soluble TNFRl inhibits TNF bioactivity in vitro. This 
recombinant protein may be useful in smdying the roles of both TNF and TNFRl in the 
pathogenesis of infectious diseases in swine. 
Introduction 
Tumor necrosis factor alpha (TNFa) is a pro-inflammatory cytokine produced by 
mononuclear phagocytes which plays an important role in both disease resistance and 
pathophysiology of many viral, bacterial and parasitic infections of humans and animals. 
Consistent with this role, there is increasing evidence to implicate TNFa in the pathogenesis of 
Salmonella infections.'^- ^ TNFa is secreted into the peripheral circulation and gut lumen after 
infection of mice with 5. typhimurium. Administration of neutralizing TNFa antibody 
abrogates the initial histological lesions of the gastrointestinal tract associated with Salmonella 
infection.^- These data suggest that TNFa mediates the early pathology of the murine 
gastrointestinal tract following Salmonella infection. The role of TNFa in salmonellosis is, 
however, not entirely negative. There is evidence to show that TNFa is required for host 
resistance and clearance of Salmonella. Late administration of TNFa antibodies to 
S. typhimurium infected mice exacerbates the course of Salmonella infection by preventing the 
suppression of bacterial growth in the reticuloendothelial system.^- ^ Moreover, macrophages 
derived from Salmonella-snscQpMe mice secrete less TNFa than do macrophages from 
5a/mone//a-resistant mice, suggesting that diminished TNFa responses by macrophages plays 
some role in susceptibility to bacterial infection. 1° Therefore, current evidence indicates that 
TNFa is a significant factor in the pathogenesis of Salmonella infections, and that TNFa may 
serve multiple roles, both harmful and beneficial over the course of infection. 
TNFa influences target cells by combining with high-affinity cell membrane receptors 
which exist as two subtypes termed the p55 TNF receptor or TNFRl, and the p75 TNF 
receptor or TNFR2. ^ ' TNFR1 mediates cytotoxic and proliferative effects of TNFa and is 
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involved in the induction of TNFa -induced tissue damage during disease. ^ 2,13 ^ soluble 
TNFR (sTNFRl) is formed by proteolytic cleavage at the cell membrane surface and circulates 
in blood as a truncated, soluble form of the receptor with fiiU TNF binding capacity, In 
humans, following a sublethal challenge with endotoxin, circulating TNF levels rise sharply, 
peak and subside. This is followed by a rise in sTNFR levels in circulation. Soluble TNF 
receptors are able to protect mice from lethal endotoxin challenge. Many other diseases, 
including cancer,'"' human immunodeficiency virus (HIV) infection,and typhoid fever'^ 
also result in increases in sTNFR in humans. In most cases, including salmonellosis, higher 
circulating soluble TNFa receptor levels correlate with worsened disease outcome, possibly 
due to their inhibition of beneficial TNFa bioactivity.^O- 21 However, in addition to their 
antagonistic role, sTNFR may also act as TNF carriers, prolonging the bioactivity of TNFa in 
vitro and in vivo .22.23 
As in the murine model, infection of swine with live S. typhimurium or S. choleraesuis, 
or administration of their endotoxins, results in significant increases in serum concentrations of 
TNFa that persist for up to six weeks after infection.24 However, the biological consequences 
of this increase in TNFa production are unknown. The TNFa produced during swine 
salmonellosis may be crucial to disease resistance, or may contribute to the pathology seen in 
salmonellosis. It is also unknown whether porcine salmonellosis results in the formation 
sTNFR as a result of receptor shedding. The objective of the present smdy was to clone, 
sequence and express biologically active porcine sTNFRl. 
Materials And Methods 
PCR-based library screening 
A porcine lung cDNA library^ was screened using a polymerase chain reaction (PGR) 
based library enrichment method.25 Primers were designed based on regions of sequence 
homology between the human26 and murine27 extracellular domains of TNFR 1. These 
primers, forward (5'AAGTGCCACAAAGGAACCTAC3') and reverse 
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(5'ATAACCAGGGGCAACAGCAC3'), amplified a 473 base pair fragment of the 
extracellular domain of porcine TNFRl from 10^ plaque forming units (PFU) of the lung 
cDNA library after thirty cycles at 94 °C- 30 sec, 57 °C - 45 sec, 72 °C -1 min. Following 
methods described elsewhere,^^ 2.5 x 10^ pfii were mixed with E. coli (strain Y1090r-) in 
100 pJ/well of Luria-Burtoni CLB) broth in a 7 x 11 matrix on a 96 well U-bottomed plate. 
After 6 hours of incubation at 37 °C in a shaking incubator, 25 nl from each well was pooled 
from each well in a row. Each pool was diluted 1:2 with water and tested by PGR with the 
above primer pair to determine if it contained phage with sTNFRl sequences. Positive pools 
were confirmed by hemi-nested PGR, using the same forward primer and an internal reverse 
primer (5'GAGGTGGGACTTTGAGT3') and by restriction enzyme digests, using PstI and 
Ddel, both of which cut the 473 bp fragment into fragments of 119 and 234 (Ddel) and 57, 65, 
138 and 212 (PstI). Wells from a positive row were tested individually, to identify positive 
wells. A positive well was used as the source of phage for a second screening, using 30x less 
phage in an 8 x 8 matrix. After the third enrichment, 5000 phage from a positive well were 
screened by plaque hybridization^^ using the 473 base pair fragment amplified as described 
above. The DNA from a single clone was isolated.29 The phage insert was then subcloned 
into an EcoRl site of Bluescript SK-*" for sequencing. The insert was sequenced in both 
directions using an automated dideoxy chain-termination method.30 
Expression and isolation of porcine sTNFRl 
Sequence encoding the extracellular domain, lacking the leader sequence, of porcine 
TNFRl (i.e. the soluble form of the receptor) was subcloned into the pFLAG-ATS expression 
vector^. This vector encodes a short (24 bp) sequence located upstream of the inserted cDNA 
of interest This upstream sequence encodes an octapeptide (FLAG) that is fused to the 
recombinant protein. The cassette also contains an outer membrane protein signal sequence, 
OmpA, which serves to direct the fusion protein to the periplasm. The resulting fusion protein 
can be recognized by antibodies specific for the FLAG peptide. PGR primers were designed to 
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correspond to the C-terminal and N-tenninal ends of the mature extracellular portion of 
TNFR1,26 and to introduce a EcoRl and a Hindlll site to enable directional subcloning into the 
multiple cloning site of pFLAG-ATS. A translational stop codon (TAA) was placed after the 
last nucleotide of the extracellular domain of pTNFRl. The vector and PGR product were cut 
with EcoRl and HindlW and the insert was ligated into pFLAG-ATS expression vector. This 
construct was transformed into E. coli (DH5a). The insert was sequenced in both directions to 
verify the insert was in-frame and no errors had occurred during PGR amplification. 
To determine the optimal expression conditions for porcine sTNFRl, bacteria 
containing either recombinant or non-recombinant pFLAG-ATS expression vector were grown 
overnight in a 37 °G shaking incubator in LB broth containing 50 |J.g/ml ampiciUin. An aliquot 
of overnight culture was diluted 1:50 in fresh LB broth containing 50 |ig/ml ampiciUin and 
0.5% glucose. After 3 hours incubation at 37 °G in a shaking incubator, the O.D.ggo was 
checked. If the O.D.ggo was between 0.2 and 0.4, a 0.5 ml aliquot was pelleted and lysed with 
reducing sample buffer (100 mM Tris, 200 mM dithiothreitol, 4% SDS, 0.2% bromophenol 
blue, 20% glycerol) prior to induction with ispropyl-|3-D-thiogaiactoside (IPTG). IPTG was 
added to a final concentration of 0.5 mM to induce production of recombinant protein. 
Gultures were grown in a shaking incubator at 37 °G or 30 °C for 2-5 hours. Aliquots were 
removed after two and four hours of induction. Equal concentrations of bacteria were achieved 
specttophotometrically (O.D.500) and cell pellets were prepared for sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE).3i 
For purification of sTNFRl, periplasmic proteins were isolated by an osmotic shocks 
Overnight cultures of DH5a cells with recombinant and non-recombinant pFLAG-ATS vector 
were prepared as above and diluted 1:50 in LB broth containing 50 ng/ml ampiciUin and 0.5% 
glucose. After 2-3 hours shaking at 37 °C, IPTG was added to a final concentration of 
0.5 mM. Bacteria were grown at 30 °C for 3-5 hours before being centrifuged at 5,000 x g. 
Pellets were washed once with 10 mMlns base (pH 8) and centrifuged at 3,500 x g for 10 
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minutes. Each pellet was resuspended in osmotic shock buffer (0.5 M sucrose, 0.03 M Tris 
base[pH 8] 1 mM EDTA) using 40 ml buffer per gram of bacteria. Bacteria were pelleted by 
centrifiigation at 3,500 x g for 10 minutes and immediately lysed with ice cold distilled water 
(40 ml/gram bacteria) and the lysed bacteria pelleted again. The supematant containing 
periplasmic proteins was frozen at -20 "C until affinity purification. 
Affinity purification 
Total periplasmic proteins were thawed and adjusted to 50 mAf Tris (pH=7.4), 150 mM 
NaCl and 1 mM CaCl2. Residual particles were cleared by centrifuging at 12,(XX) x g at 4 °C 
for 30 minutes. Supematants were loaded onto a Ml-affinity column"^ by gravity flow. After 
loading three one milliliter (I ml) affinity columns with 100-200 mis of clarified periplasmic 
proteins, the columns were washed three times with fresh Tris-buffered saline (TBS- 50 mM 
Tris [pH=7.4], 150 mAf NaCl) with 1 mM CaCb added. Bound proteins were then eluted by 
incubating the column with successive 1 ml aliquots of TBS with 2 mM EDTA for 30 minutes 
for the first fraction and 10 minutes for successive fractions. Fractions 1-5 were pooled prior 
to testing for bioactivity. 
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Western blots and silver staining-
Standard methods were used for gel electrophoresis and transfer to a solid support'.^^ 
Samples were loaded in parallel onto two 12.5% discontinous polyacrylamdde gels that were 
run simultaneously. One gel was either Coomassie blue (whole cell lysates) or silver-stained 
(purified proteins),33 and the second gel transferred onto Immobilon' membrane. After 
transfer, the membrane was blocked overnight in 5% skim milk- and incubated 4 hours at 37 °C 
with anti-FLAG monoclonal antibody (Ml®) at a concentration of 10 jig/ml to detect the FLAG-
TNFRl fusion protein. Finally, membrane was washed three times in TBS with 0.2% skim 
milk- and an alkaline phosphatase conjugated goat anti-mouse IgG (1:10,0(X)^ was used to 
detect bound Ml antibody. Naphthol-AS-MX^ (0.75 |J,g/ml) and fast red TR^ (1.5 ng/nil)were 
used as a substrate to visualize membrane-bound alkaline phosphatase. 
TNFa cytotoxicity assays 
TNFa cytotoxicity assays were modifications of previously described assays.^^ 
PK(15) cells were washed in Eagles Minimal Media ^ (EMEM) with 5% fetal bovine semm and 
diluted to 2.5 x 10^ cells/ml and added to 96 well plates at 100 jil per well. Plates were 
incubated overnight in a 37 °C, 5% CO2 incubator. Media was removed and replaced with 
100 fil per well Iscove's medium cotaining 0.5% bactopeptone® and 3 |ig/ml actinomycin 
Plates were incubated for two hours at 37 °C and 5% CO2. To determine the bioactivity of 
porcine sTNFRI, varying concentrations of either affinity purified FLAG-sTNFRl protein or 
FLAG peptide alone (40 ng/ml-5 (ig/ml) were added to media aliquots containing 10 pg/ml 
porcine TNT*". The samples were co-incubated in a 37 °C, 5% CO2 incubator for 30 minutes 
before being added at 100 ^U/well in triplicate into the plates containing actinomycin D-treated 
PK(15) cells. The plates were then incubated in a 39 °C, 5% CO2 incubator for 18-20 hours. 
Media was aspirated fi"om all wells before addition of 100 ^il/well dimethylthiazol 
diphenyltetrazolium bromide (MTT)^ at 1 mg/ml in phosphate-buffered saline (PBS). The 
plates were then incubated for 2 hours, followed by replacement of media with acidified 
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isopropanol (36 mM HCl in isopropanol), which both lysed cells and solubilized MTT 
crystals. Plates were then shaken and absorbance at 570 nm determined using a microplate 
reader'. Cells that had been lysed with distilled water prior to the addition of MTT were used 
as blanks. Percent cytotoxicity and percent inhibition were calculated with the following 
equations: 
A57o(No TNFa Added) - A57(,(Test) 
% Cytotoxicity = x 100 
A57o(No TNFa Added) 
% Cytotoxicity (FLAG Added) - % Cytotoxicity (FLAG-sTNFRl 
Added) 
% Inhibition = x 100 
% Cytotoxicity (FLAG Added) 
Results 
Isolation and sequencing of porcine TNFRl 
The initial frequency of the porcine TNFRl gene in the lung cDNA library was 1 in 2 x 
10^ phage. After three rounds of eiuichment, the target gene was present at a frequency of 1 in 
7 X 10^ phage (Table 1). Plaque hybridization was used to isolate a single clone containing a 
927 bp gene fragment which encodes part of the 5' untranslated region (43 bp), the entire 
extracellular (564bp, 188 A.A.), transmembrane domain (63 bp, 21AA), and part of the 
intracellular domain (225 bp, 75 A.A.)(Fig. 1). The portion of the 5' UTR sequence obtained 
is 86% homologous to human and 83% homologous to murine sequence in this region (Fig. 
1). This sequence is nearly identical to that reported by Suter and Pauli.^s The fourth amino 
acid from the start codon in our sequence is proline, in contrast to a serine as previously 
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reported. The difference in amino acid sequence is the result of a single substitution of C for T 
at nucleotide position #10 in our sequence. There is also a silent G to C mutation at position 
18, with both sequences encoding valine. The amino acid sequence homology of our porcine 
TNFRl fragment with human, murine and rat TNFRl is 70.4% , 61.9% and 61.5% , 
respectively (Fig. 2). After subcloning the extracellular domain of TNFRl into pFLAG-ATS, 
sequence analysis confirmed that the inserted truncated porcine TNFRl sequence was in the 
correct reading frame relative to the vector start sequence and that no errors had occuiied 
during PGR amplification 
Expression and immunoblotting of the extracellular domain of TNFRl 
The predicted molecular weight of the fiision protein (FLAG with sTNFRl) was 29.2 
kDa with the OmpA signal peptide attached and 26 kDa without OmpA. DH5a cells 
transformed with pFLAG-TNFRl and exposed to IPTG expressed a 29.2 kDa protein that was 
visible upon Coomassie blue staining of a SDS-PAGE gel (Fig. 3 A, lanes 6-7, 10-11) and 
detectable by Ml monoclonal antibody on a Western blot (Fig. 3B, lanes 6-7, 10-11). The 
29.2 kDa fusion protein represented approximately 4.6% of the total cellular protein after four 
hours of induction at 37 °C, and 4.7% of the total cellular protein after the same time of 
induction at 30 °C. The 29.2 kDa protein was not detectable by Coomassie blue staining of 
total cell lysates from untransformed, non-recombinant pFLAG-ATS transformed, or 
uninduced cells. However, the Western blot revealed minor expression of the 29.2 kDa 
protein in uninduced cultures transformed with pFLAG-TNFRl (Fig. 3B, lanes 5, 8-9, 12-
13), indicating low levels of constimtive expression. A 26 kDa band corresponding to the 
molecular weight of the FLAG-TNFRl fusion protein without the OmpA signal peptide was 
detected via immunoblotting (Fig. 3B). 
Isolation of FLAG-TNFRl 
Use of the Ml-affinity column as a purification procedure removed most of the 
contaminating proteins and concentrated the FLAG-TNFRl protein (Fig. 4 A). The 29 kDa 
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FLAG-TNFRl protein was bound to the column and was detectable by Western blot after 
elution (Fig. 4B). Affinity purification of periplasmic proteins resulted in a yield of 
120-150 fig porcine sTNFRl per liter of DH5a culture induced for 4-5 hours at 30 °C. 
Inhibition ofTNF: Bioactivity of sTNFRl 
Affinity purified porcine sTNFRl inhibited recombinant porcine TNFa-induced 
cytotoxicity (Fig. 5). There was a dose-dependent reduction in TNF bioactivity as determined 
by SAS36 (Pearson's correlation coefficient = 0.482, p = 0.0196). Approximately 70% 
inhibition of TNFa bioactivity was seen when sTNFRl at a concentration of 5 |Xg/ml was pre-
incubated with 10 pg/ml porcine TNFa. This inhibition decreased with decreasing 
concentrations of sTNFRl, with 150 pg/ml sTNFRl being able to inhibit approximately 35% 
of the TNFa -induced cytotoxicity to PK(15) target cells. 
Discussion 
The nucleotide sequence of the gene fragment of porcine TNFRl reported in this study 
(927 bp) is nearly identical with that previously reported,^  ^ differed by only one amino 
acid at the protein level. The small divergence between the structure of the two porcine TNFRl 
genes could reflect the different cell sources of the cDNA. Suter and Pauli derived their clone 
from an immortalized cell line, PK(15), while our cDNA library was derived from normal lung 
tissue. Genetic variations resulting in multiple alleles for TNFRl in the swine population or 
small errors in reverse transcription or PGR may also account for the minor discrepancies. 
There are two amino acids, asparagine and valine, that are well conserved among 
human,26 mouse,27 and rat^^ TNFRls. The position of these two key amino acids at the 
#172 and #173 position (human gene numbering^^), respectively, are evidently essential for 
correct cleavage of human TNFRl. Mutagenesis of either amino acid reduces shedding of 
sTNFRl by 50%, whereas mutagenesis of both abolishes cleavage of the sTNFRl almost 
completely.38.39 However, we found that the porcine TNFRl sequence contains neither an 
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asparagine nor a valine residue at these positions. One possibility is that a soluble, truncated 
form of TNFTll is not generated in swine. More likely possibilities, however, are that 
sTNFRl cleavage in swine is performed by a protease that recognizes a different structural 
domain than the corresponding human protease,^^ or that alternate RNA splicing generates 
sTNFRl in swine.^o 
Recombinant porcine sTNFRl was expressed by E.coli after subcloning of the region 
of DNA that codes for the mature extracellular domain of porcine TNFRl. However, yield of 
sTNFRl was low (120-150 fig/L) because of poor solubility of the recombinant protein, a 
problem also reported with the expression of human TNFRl Growth at lower temperatures 
(30 °C) which generally favors solubility^  ^ (jiji not, however, significantly improve yields. 
The use of another expression strain of E. coli (BL21) also failed to increase yields (data not 
shown). 
The fusion protein synthesized by this system was 29 kDa in size, consistent with the 
predicted combination of the sTNFRl (24.8 kDa) with the FLAG (1.5 kDa) and OmpA signal 
peptide (2.8 kDa). The size of mature porcine TNFRl (464 A.A.) is identical to that of human 
sTNFRl (464 A.A.), and is consistent with the homology between human and porcine genes. 
The porcine fusion protein was biologically active when present in soluble form in culture 
medium. Recombinant sTNFRl blocked the cytolytic effect of exogenous porcine TNF, in a 
cytotoxicity bioassay. While there was a great deal of variation in the bioactivity of each 
preparation, there was a positive correlation between the amount of sTNFRl added and the 
amount of protection seen. We interpret this dose-related result as evidence that sTNFRl 
bound to TNFa in the culture medium and prevented interaction of TNFa with membrane-
bound TNF receptors present on cultured PK(15) cells, thereby inhibiting cell death. 
The relatively large excess of recombinant sTNFRl required to antagonize TNFa may 
have been due to the presence of the FLAG or OmpA peptides in the fusion protein, although 
there is no evidence from previous expression studies that these small peptides impede 
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bioactivity.'^^' ^  The relatively modest amount of bioactivity seen in our preparations could 
also be due the homologous nature of the PK(15) bioassay system. Other groups testing the 
bioactivity of prokaryotically-derived, recombinant human TNFRl used heterologous, murine 
cells.'^''^^ It is likely that the homologous, eukaryotically-expressed receptors on the surface 
of the PK(15) target cells were better able to compete with the recombinant soluble TNFRl for 
binding of TNFa than are heterologous receptors on murine cells. The lack of the 
asparagine/valine site in porcine TNFRl may result in a different cleavage site. Since our 
soluble TNFRl molecule was based on human sTNFRl data, a change in the cut site could 
change the bioactivity of the recombinant molecule. Another explanation is that 
posttranslational changes, such as correct re-folding of the sTNFRl protein, are needed for 
maximal bioactivity. Therefore, while this particular E. coli expression system provided 
sufficient recombinant protein for preliminary studies, a eukaryotic expression system may be 
preferable for production of accurately re-folded recombinant sTNFRl with more bioactivity. 
In summary, we present evidence to show that we have cloned cDNA for the 
extracellular domain of porcine TNFRl from a normal cell source and obtained a bioactive 
form of sTNFRl. The anti-TNFa capacity of recombinant sTNFRl suggests that this reagent 
may have a potential therapeutic role in swine infectious diseases in which excess TNFa 
causes deleterious effects. Additionally, the recombinant protein may be used to develop 
antibodies that can be used to detect sTNFRl levels in swine. Finally, we speculate that serum 
levels of sTNFRl may serve as a diagnostic aid in porcine systemic and gastrointestinal 
diseases, as it does in similar human disease states.^! - ^6 
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Footnotes 
° Clontech, Palo Alto, CA 
'' Stratagene, La Jolla, CA 
" Kodak Scientific Imaging Systems, New Haven, CT 
Gibco-BRL, Grand Island, NY 
' Immobilon, Millipore, Beford, MA 
^ Sigma Chemical Co. St. Louis, Mo 
® Difco,Surrey, UK 
Endogen, Cambridge, MA 
' Dynatech, Chantilly, VA 
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Table 1. PCR-based library enrichment for porcine TNFRl sequences in a 
porcine lung library. 
Enrichment PFUs/^il PCR positive dilution Frequency 
Original lxio '7  1:5 1 in 2 X 10^ 
Primary 5x 10^ 1:40 1 in 1.2 x 10"^ 
Secondary 3x 10^ 1:50 1 in 5.6 x 10^ 
Tertiary 7x 10^ 1:100 1 in 7 X 10^ 
Figure 1. Sequence of the p55 porcine TNFRl fragment. The cDNA isolated included 
927 bp of the open reading frame of porcine TNFRl with 43 bp of the 5' UTR. 
Primers with restriction sites that were used to subclone the mature extracellular domain 
into pFLAG-ATS are indicated with arrows. The transmembrane domain is 
underlined. 
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-42 CCTGAGCCCTGATGGGGGAGTGAGAGGCCACAGCTGGCCGGAC ATG GGC CTC CCC ACC GTC CCT 21 
1 Met Gly Leu Pro Thr Val Pro 7 
22 GGC CTG CTG CTG CCA. CTG GTG CTC CGG GCT CTG TTG GTG GAT GTG TAC CCC GCA 75 
8 Gly Leu Leu Leu Pro Leu Val Leu Arg Ala Leu Leu Val Asp Val Tyr Pro Ala 25 
> 
76 GGG GTC CAC GGG CTG GTC CTT CAC CCT GGG GAC CGG GAG AAG AGA GAG AGT TTG 129 
26 Gly Val His Gly Leu Val Leu His Pro Gly Asp Arg Glu Lys Arg Glu Ser Leu 43 
130 TGT CCC CAA. GGA AAA TAC AGC CAC CCT CAA AAT AGG TCC ATT TGC TGC ACG AAG 183 
44 Cys E>ro Gin Gly Lys Tyr Ser His Pro Gin Asn Arg Ser lie Cys Cys Thr Lys 61 
184 TGC CAC AAA GGC ACC TAC CTA CAC AAT GAC TGT CTG GGC CCG GGG CTG GAC ACG 237 
62 Cys His Lys Gly Thr Tyr Leu His Asn Asp Cys Leu Gly Pro Gly Leu Asp Thr 79 
238 GAC TGC AGG GAG TGC GAC AAT GGC ACC TTC ACT GCA TCA GAG AAC CAC CTC ACA 291 
80 Asp Cys Arg Glu Cys Asp Asn Gly Thr Phe Thr Ala Ser Glu Asn His Leu Thr 97 
292 CAA TGC CTG AGC TGC TCC AAG TGC CGG AGT GAA ATG TCC CAG GTG GAG ATT TCT 345 
98 Gin Cys Leu Ser Cys Ser Lys Cys Arg Ser Glu Met Ser Gin Val Glu lie Ser 115 
346 CCG TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGA AAG AAC CAG TAC CGG 399 
116 Pro Cys Thr Val Asp Arg Asp Thr Val Cys Gly Cys Arg Lys Asn Gin Tyr Arg 133 
400 AAG TAC TGG AGT GAG ACT CTT TTC CAG TGT CTG AAC TGC AGC CTC TGC CCC AAC 453 
134 Lys Tyr Trp Ser Glu Thr Leu Phe Gin Cys Leu Asn Cys Ser Leu Cys Pro Asn 151 
454 GGC ACA GTG CAA CTC CCC TGC CTG GAG AAA CAG GAC ACC ATC TGC AAC TGC CAC 507 
152 Gly Thr Val Gin Leu Pro Cys Leu Glu Lys Gin Asp Thr lie Cys Asn Cys His 169 
508 TCG GGG TTC TTT CTA AGA GAT AAG GAG TGT GTC TCC TGT GTT AAC TGT AAG AAC 561 
170 Ser Gly Phe Phe Leu Arg Asp Lys Glu Cys Val Ser Cys Val Asn Cys Lys Asn 187 
< 
562 GCA GAC TGC AAG AAT TTA TGT CCA GCC ACA TCT GAA ACT CGT AAC GAC TTT CAG 615 
188 Ala Asp Cys Lys Asn Leu Cys Pro Ala Thr Ser Glu Thr Arg Asn Asp Phe Gin 205 
616 GAC ACA GGC ACC ACG GTG CTG TTG CCG CTG GTG ATC TTC TTT GGT CTT TGC CTG 669 
206 Asp Thr Gly Thr Thr Val Leu Leu Pro Leu Val lie Phe Phe Glv Leu Cvs Leu 223 
670 GCA TTC TTC CTC TTC GTT GGC TTA GCT TGC CGC TAC CAA CGG TGG AAA CCA AAG 723 
224 Ala Phe Phe Leu Phe Val Glv Leu Ala Cys Arg Tyr Gin Arg Trp Lys Pro Lys 241 
724 CTC TAC TCC ATT ATT TGT GGG AAA TCG ACT CCT GTA AAG GAG GGA GAG CCG GAG 777 
242 Leu Tyr Ser He He Cys Gly Lys Ser Thr Pro Val Lys Glu Gly Glu Pro Glu 259 
778 CCC CTG GCC ACA GCT CCA AGC TTC GGT CCC ATC ACG ACT TTC AGT CCC ATC CCA 831 
260 Pro Leu Ala Thr Ala Pro Ser Phe Gly Pro He Thr Thr Phe Ser Pro He Pro 277 
832 AGC TTC AGT CCC ACC ACG ACC TTC AGT CCT GTC CCA AGC TTC AGT CCC ATC TCC 885 
278 Ser Phe Ser Pro Thr Thr Thr Phe Ser Pro Val Pro Ser Phe Ser Pro He Ser 295 
886 AGT CCC ACC TTC ACC CCG TGT GAC TGG TCC AAC ATC AAA GTC 927 
296 Ser Pro Thr Phe Thr Pro Cys Asp Trp Ser Asn He Lys Val 309 
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pig MGLPTVPGLL LPLVLRALLV DVYPAGVHGL VLHPGDREKR ESLCPQGKVS HPQNRSICCT 
rat 1 .PSL OJ A ..K.N 
mouse S...L...M .IH.S..T.. .PSL D V .SK.N 
human ...S...D LE... GI..S..I.. .PSL D.V I ..Q.N 
120 
pig KCHKGTYLHN DCLGPC3LDTD CHECENGTFT ASENHLTQCL SCSKCRSEMS QVEISPCTVD 
rat VS ..PS..QE.V .EV K Q..VR KT. .K. .F KA. 
mouse VS ..PS..R. .V EK Q.Y.R KT..K QA. 
human Y. ..P...Q ES.S RH K. .G S 
180 
pig RDTVCGCRKN QYRKXWSETL FQCLNCSLCP NGTVQLPCLE KQDTICNCHS GFFLRDKECV 
rat M K.. .FQR.L...H ...VD..P.F TI..K. . .N.V A SQI. .T 
moijse K KE. .FQR.L...H ...VD..P.F TI..K. T.N.V A ES... 
htanan H N. .. .F L TI..K. T.N.V A ES... 
240 
pig SCVNCKNA-D CKNLCP-ATS ETPNDFQETG TTVLLPLVXF FGLCLAFFLF VGLACRYQRW 
rat P.SH..KNQE .MK. .L-PPV ANVTNP. .S. .A L L..IC IS.L. . .PQ. 
mouse P.SH..KNEE .MK. .LPPPL ANVTNP. .S. .A LL LS.I. IS.M...PR. 
hvrnian ..S...KSLE .TK..L-PQI .NVKGTE.S LSL. . I. .MY 
300 
pig KPKLYSIICG KSTPVKBGEP EPLATAP-SF GPITTFSPIP SFSPTTTFSP VPSFSPISSP 
rat R.RV R D.A V.G .GIV.K.LTP AS.PA. . .N. G.N. .LG. .T T.R. .HPV.S 
mouse ANVTNPQDS. D.A V.G .GIV.K.LTP AS.PA.. .N. G.N. .LG. .T T.R. .HPV.S 
human .S V E L .GTT.K.. .L A.NPS. . .T. G.T. .LG STFT. .S 
pig T FTPC DWSNIKV 
rat .PISPV.G.S N.H.FVPPVR 
mouse .PISPI.G.S N.H.FMPPVS 
human YT.G .CP.FAAPRR 
350 
EWPT.QGAD PLLYGSLNPV PIPAPVRKWE 
EWPT.QGAD PLLYESLCSV PAPTSVQKWE 
EVAPPYQGAD PILATALASD PIPNPLQKWE 
Figure 2 Amino acid comparison of porcine TNFRl to human, murine and rat, TNFRl. The 
amino acid homology of our porcine TNFRl fragment with human, murine, and rat TNFRl is 
70.4%, 61.9%, and 61.5%, respectively. 
Figure 3. Induction of fusion protein expression. Low molecular weight standards are 
identified in the margin (lane 0). Untransformed DH5a cells (lanes 1&2), or those 
transformed with pFLAG-ATS (lanes 3 &4) or pFLAG-TNFRl (lanes 5-13) were grown 
at 37 °C (lanes 1-9) or 30 °C (lanes 10-13). IPTG was added to induce production of 
FLAG-TNF-Rl for the times indicated (lanes 2,4, 6-7, 10, 11). A: Coomassie blue-
stained gel. B: Western blot of an identically mn gel. 
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Figure 4. Purification of FLAG-TNFRl. Low molecular weight standards are identified in the 
margin (lane 0). Pre (lanel) and post-column purified (Iane2) periplasmic proteins were loaded 
onto a 12.5% SDS-PAGE gel (10 filTlane). A: Silver stain of affinity purified fractions. B: 
Western blot of an identically run gel. 
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Figiire 5. Bioactivity of sTNFRl. Varying concentrations of recombinant pFLAG-TNFRl or 
FLAG (150 ng/ml-S M-g/ml) were co-incubated with a CD50 dose of porcine TNFa. The 
protective effect of sTNFRl was determined as described in Materials and Methods. Data from 
three experiments were combined and are expressed as mean values ± SEM. 
92 
GENERAL CONCLUSIONS 
Tumor necrosis factor is a pro-inflammatory cytokine that is expressed early in an 
infection. This cytokine activates both leukocytes and endothelium, facilitating the movement 
of inflammatory cells from circulation to sites of infection or injury (19). In certain instances, 
this mobilization is beneficial and aids in host defense. These instances include infection with 
intracellular bacteria (6, 9) or parasites (7). In some instances, TNF is overproduced and is a 
major contributing factor to disease pathology. In humans, acute infection, especially with 
Gram-negative bacteria causes a sharp rise in the level of circulating TNF, which contributes 
significantly to septic shock (18) and adult respiratory distress syndrome (5). Patients with 
chronic diseases, such as cancer or AIDS often have slighdy elevated TNF levels over a long 
period of time, which may contribute to the cachexia associated with these diseases (4, 19). 
Humans are not the only species to suffer the consequences of TNF overproduction. 
Several porcine diseases, such as mycoplasmal pneumonia (2) and salmonellosis (17) stimulate 
the production of TNF in vivo. Pigs are also often used as a model for human disease and 
show elevated serum TNF levels during experimental endotoxemia and sepsis (13). 
In order to study the role of TNF during these disease processes, a sensitive assay to 
detect TNF in porcine biological samples is needed. In the first part of this project, we 
compared the sensitivities of a newly developed PK(15)-based bioassay to that of a more 
commonly used WEHI 164(13)-based assay. Murine WEHI 164(13) cells were fifty times 
more sensitive to murine TNF and fifteen times more sensitive to human TNF-mediated lysis. 
Porcine PK(15) cells, however, were four times more sensitive to recombinant porcine TNF 
and fifteen times more sensitive to porcine serum TNF-mediated lysis. Therefore, the 
PK(15)-based bioassay may be more sensitive and particularly usefiil in studying swine 
diseases where a broad range of TNF levels are expected. 
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While bioassays are able to detect free TNF, they are unable to detect TNF that is either 
degraded or bound by soluble TNF binding proteins (3). These binding proteins are the 
proteolytically cleaved extracellular domains of TNF receptors (12). These soluble receptors 
retain the capacity to bind TNF and may either inhibit or potentiate the bioactivity of TNF 
in vitro (1, 14) or in vivo (11). The human and murine genes for TNF receptors (TNFRl) 
have been isolated and been found to interact with TNF in a species specific fashion (10,15, 
16). Therefore, the objectives for the second part of this project were to isolate, sequence and 
determine the bioactivity of porcine TNFRl. To do this we first designed PGR primers based 
on human and murine TNFRl sequences. Using these primers, we amplified a 473 bp 
fragment from PK(15) cDNA and a porcine lung cDNA library. We then used a PCR-based 
library enrichment to isolate a clone encoding part of the 5' untranslated region (UTR), the 
entire extracellular domain (188 amino acids), the transmembrane domain (21 amino acids) and 
part of the intracellular domain (75 anoino acids). The region encoding the extracellular 
domain, lacking the porcine signal sequence, was subcloned into an expression vector and 
expressed as a FLAG fusion protein in E. coli. Using an anti-FLAG affinity column, we 
purified the fusion protein, which resulted in a yield of approximately 120-150 |ig per liter of 
culture. The purified protein neutralized 70% of TNF-mediated cytotoxicity in a PK(15)-based 
bioassay at a concentration of 5 |ig/ml. The relatively low yield may be the result of the 
expression system used. Members of the TNF receptor family have cysteine-rich extracellular 
domains, which makes them relatively insoluble when expressed in prokaryotic cells (20). 
In stumnary, the primary objectives of this project have been met. The PK(I5)-based 
bioassay is superior to the WEHI 164(13)-based bioassay at detecting TNF in porcine semm 
samples. This is useful information when designing future in vivo experiments. A 
recombinant form of porcine TNFRl has been expressed and has bioactivity. A next 
generation porcine TNFRl fusion protein may be created using the sequence information and 
cloned gene from this project. A better fusion protein would be an immunoadhesin, consisting 
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of the Fc portion of a porcine immunoglubulin with the extracelluar domain of porcine TNFRl 
in the place of the Fab fragments. Immunoadhesins constructed with human TNF receptors 
have a greater binding capacity and serum half-life than do soluble human TNF receptors (8). 
The current soluble porcine TNFRl fusion protein may also be a useful tool in developing 
monoclonal antibodies, which could be used to create a porcine TNFRl enzyme-linked 
immunosorbent assay (ELIS A) to detect soluble receptors in circulation. The accurate 
measurement of TNF and soluble TNFRl could reveal the roles of both TNF and TNFRl in 
the pathogenesis of infectious diseases of swine and be used as a model for human disease. 
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